Fusion doses first subject in Phase I/II solid tumor therapy trial

Fusion doses first subject in Phase I/II solid tumor therapy trial

Submitted by admin on August 30, 2022 - 11:53am
Source: 
Clinical Trials Arena
News Tags: 
Fusion Pharmaceuticals
solid tumors
clinical trials
FPI-1966
Headline: 
Fusion doses first subject in Phase I/II solid tumor therapy trial
snippet: 

FPI-1966 acts on and offers an alpha-emitting medical isotope, actinium-225, to cancer cells that express FGFR3.

Do Not Allow Advertisers to Use My Personal information